AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy. Yan B, Claxton D, Huang S, Qiu Y, et al. Exp Hematol 2020;87:13-19.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Yan B, Claxton D, Huang S, Qiu Y, et al. AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy. Exp Hematol 2020;87:13-19.
PMID: 32569759